Fulcrum Therapeutics
Latest round
- Series B
Last raised
- Aug 2018
Total raised
- $135M
Investors
- 10
About Fulcrum Therapeutics
Fulcrum Therapeutics, Inc. is a US-based biopharmaceutical company focused on developing innovative therapies for genetically defined diseases, particularly those with significant unmet medical needs. Sapir, Fulcrum Therapeutics, Inc. operates out of Cambridge, US, and specializes in targeted treatments for genetic disorders., a portfolio company of Boxer Capital, Samsara BioCapital, Perceptive Advisors, EcoR1 Capital, Casdin Capital, Alyeska Investment Group, Monashees, Timefolio Capital, Section 32, 6 Dimensions Capital, Casdin Capital, Foresite Capital, Fidelity Investments, Sanofi Ventures, Leerink Partners, GV, and Third Rock Ventures, agreed to merge into Slate Medicines, a portfolio company of Forbion, Foresite Capital, and RA Capital Management. The transaction is subject to customary closing condition and is expected to be completed in the fourth quarter of 2026. Following the transaction, the combined company is expected to be renamed Slate Medicines and trade on Nasdaq under the ticker symbol SLTE.Fulcrum Therapeutics is dedicated to developing innovative treatments for patients with genetically defined diseases, particularly those with high unmet medical needs. The company's lead product, pociredir, is currently undergoing clinical trials aimed at treating sickle cell disease (SCD), focusing on modulating gene expression to address the underlying genetic causes of this condition. In addition to pociredir, Fulcrum is actively exploring other programs within its research pipeline, including potential treatments for beta-thalassemia. The target customer base includes healthcare providers and institutions that cater to affected patient populations, primarily in North America and Europe, where the prevalence of these genetic disorders is significant.Fulcrum Therapeutics engages in a structured transaction model that typically involves partnerships and collaborations with healthcare organizations and research institutions.30 mn. The company's flagship product, pociredir, represents a significant focus in its revenue strategy, aligning with the needs of healthcare providers seeking innovative treatment options for SCD patients. While specific pricing plans for products are not disclosed, the company is positioned to establish pricing based on the value provided by its therapeutics and their ability to address unmet medical needs in the genetic disease market. The firm’s revenue model may also be complemented by potential licensing agreements and collaborations with biotechnology firms that share similar therapeutic goals.
Who invested in Fulcrum Therapeutics
10 investors across 3 rounds
See all investors in Fulcrum Therapeutics
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Fulcrum Therapeutics
Who invested in Fulcrum Therapeutics?
Fulcrum Therapeutics has 10 investors on record across 3 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Fulcrum Therapeutics raised?
Fulcrum Therapeutics has raised 3 venture rounds. Sign up free to see how much each round raised and the total.
When did Fulcrum Therapeutics last raise money?
Fulcrum Therapeutics's most recent round on record is a Series B, in Aug 2018.
What does Fulcrum Therapeutics do?
Fulcrum Therapeutics is a biotechnology company.
Where is Fulcrum Therapeutics headquartered?
Fulcrum Therapeutics is headquartered in Cambridge, US.
Which VCs invest in companies like Fulcrum Therapeutics?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at Fulcrum Therapeutics's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series B
Raising like Fulcrum Therapeutics? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.